What triggered the latest interest in Pennant Group (PNTG)?
Pennant Group (PNTG) has drawn fresh attention after issuing 2026 revenue guidance of US$1.13b to US$1.17b and reporting its fourth quarter and full year 2025 results, alongside a reaffirmed positive analyst view.
See our latest analysis for Pennant Group.
The share price has pulled back slightly in the last day, with a 1-day share price return of 0.72% decline. That follows a strong run, including a 19.66% year to date share price return and a 44.16% total shareholder return over the past year, which suggests momentum has been building around recent earnings and 2026 guidance.
If Pennant Group's update has you thinking about where else growth stories might emerge in healthcare, it could be a good time to check out 32 healthcare AI stocks as another way to source ideas.
With the shares rising significantly over the past year and trading about 14% below the latest analyst target, the key question now is whether Pennant Group still trades at a discount or whether the market is already pricing in future growth.
Most Popular Narrative: 11.2% Undervalued
At a last close of $33.30 versus a narrative fair value of $37.50, Pennant Group is framed as attractively priced, with the gap tied to long term cash flow potential rather than short term headlines.
The continued shift in health care delivery toward lower cost, home based settings reinforced by government and payer priorities to control costs and improve patient satisfaction directly benefits Pennant's core business lines, and as patients and families increasingly prefer home care, management expects above industry growth rates and margin expansion from operating leverage.
Curious what it takes for this valuation to stack up? The narrative leans on brisk revenue expansion, rising margins and a richer future earnings multiple. The exact mix of those ingredients might surprise you.
Result: Fair Value of $37.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to weigh meaningful risks, including potential reimbursement cuts from the proposed 2026 CMS home health rule, as well as ongoing labor cost and staffing pressures.
Find out about the key risks to this Pennant Group narrative.
Another way to look at Pennant Group's valuation
The earlier narrative leans on long term cash flows and a fair value of $37.50, but the current P/E of about 39x tells a different story. That is richer than both the US Healthcare average of 23.2x and a fair ratio of 24.8x, even though it sits below a 94x peer average. For you, that gap can feel like either valuation risk or a premium that needs strong execution to hold up. Which side of that trade off do you think you are on?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals on Pennant Group leave you unsure, take a closer look at the full picture yourself and move quickly to shape your own view with 3 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Pennant Group has sparked your interest, do not stop here. You may miss plenty of other angles if you only focus on a single company.
- Spot potential value opportunities early by checking out screener containing 24 high quality undiscovered gems before they land on everyone else's radar.
- Protect your downside by scanning 73 resilient stocks with low risk scores that score well on stability and resilience.
- Strengthen your core holdings with solid balance sheet and fundamentals stocks screener (41 results) that pair financial discipline with solid fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com